SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

SG Americas Securities LLC acquired a new stake in Arbutus Biopharma Co. (NASDAQ:ABUS) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 52,869 shares of the biopharmaceutical company’s stock, valued at approximately $204,000.

A number of other institutional investors have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its holdings in shares of Arbutus Biopharma by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 57,323 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 4,191 shares in the last quarter. Premier Path Wealth Partners LLC grew its holdings in shares of Arbutus Biopharma by 18.0% in the second quarter. Premier Path Wealth Partners LLC now owns 36,000 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 5,500 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Arbutus Biopharma by 22.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 6,649 shares in the last quarter. Verus Capital Partners LLC grew its holdings in Arbutus Biopharma by 30.5% during the 1st quarter. Verus Capital Partners LLC now owns 41,935 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 9,800 shares in the last quarter. Finally, nVerses Capital LLC acquired a new position in Arbutus Biopharma during the 2nd quarter worth approximately $34,000. Institutional investors and hedge funds own 43.79% of the company’s stock.

Analysts Set New Price Targets

ABUS has been the subject of several analyst reports. StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. JMP Securities boosted their price target on shares of Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday, August 2nd. Finally, Jefferies Financial Group boosted their price target on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.25.

Arbutus Biopharma Trading Down 1.0 %

Shares of NASDAQ:ABUS opened at $4.03 on Wednesday. The company has a market capitalization of $760.53 million, a PE ratio of -9.16 and a beta of 1.91. Arbutus Biopharma Co. has a twelve month low of $1.69 and a twelve month high of $4.72. The firm has a 50 day simple moving average of $4.00 and a 200-day simple moving average of $3.50.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The company had revenue of $1.73 million for the quarter, compared to analysts’ expectations of $1.54 million. Arbutus Biopharma had a negative return on equity of 66.68% and a negative net margin of 766.20%. During the same quarter in the prior year, the firm posted ($0.10) EPS. As a group, equities research analysts predict that Arbutus Biopharma Co. will post -0.38 EPS for the current fiscal year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.